Loading...
Market
Which region will first approve AstraZeneca's CSPC Lp(a) drug by 2028?
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Regulatory approval announcements from AstraZeneca, CSPC Pharmaceutical Group Ltd, or relevant health authorities
Story
AstraZeneca to Pay Up to $2 Billion for CSPC's AI-Developed Lp(a) Cardiovascular Drug
Oct 7, 2024, 09:00 AM
AstraZeneca has entered into an exclusive licensing agreement with Hong Kong-listed CSPC Pharmaceutical Group Ltd, agreeing to pay up to $2 billion to enhance its cardiovascular pipeline. The deal includes a $100 million upfront payment and potential milestone payments totaling up to $1.9 billion. The licensed therapy is a preclinical small molecule targeting lipoprotein(a), or Lp(a), developed using CSPC Pharma's AI platform. This lipid-lowering drug aims to address cardiovascular diseases by reducing Lp(a) levels. The agreement underscores AstraZeneca's commitment to leveraging innovative technologies from Chinese biotech firms to strengthen its position in the cardiovascular market.
View original story
Similar markets
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
United States • 25%
European Union • 25%
Asia-Pacific • 25%
Other regions • 25%
Canada • 25%
European Union • 25%
Japan • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
None of the above • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
European Union • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%